Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 37 of the 55 sources its claims cite were checked for support.

Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight

Open access
Lee, Se-Jin, Lehar, Adam, Meir, Jessica U., Koch, Christina, Morgan, Andrew, Warren, Lara E., Rydzik, Renata, Youngstrom, Daniel W., Chandok, Harshpreet, George, Joshy, Gogain, Joseph, Michaud, Michael, Stoklasek, Thomas A., Liu, Yewei, Germain-Lee, Emily L. · 2020 · Proceedings of the National Academy of Sciences

Abstract

mice, were largely maintained during spaceflight. Systemic inhibition of MSTN/activin A signaling using a soluble form of the activin type IIB receptor (ACVR2B), which can bind each of these ligands, led to dramatic increases in both muscle and bone mass, with effects being comparable in ground and flight mice. Exposure to microgravity and treatment with the soluble receptor each led to alterations in numerous signaling pathways, which were reflected in changes in levels of key signaling components in the blood as well as their RNA expression levels in muscle and bone. These findings have implications for therapeutic strategies to combat the concomitant muscle and bone loss occurring in people afflicted with disuse atrophy on Earth as well as in astronauts in space, especially during prolonged missions.

Overview

CoChat Summary

## TL;DR

This mouse ISS study tested whether blocking myostatin/activin A signaling with ACVR2B/Fc or genetic Mstn deletion could protect against microgravity-induced muscle and bone loss. The paper reports that ACVR2B/Fc significantly increased lean mass and bone measures in flight mice and helped restore both muscle and bone after return to Earth.

## Key findings

  • Muscle loss from spaceflight: In wild type mice exposed to microgravity for 33 days, lean body mass was 9% lower, and weights of the pectoralis, triceps, quadriceps, gastrocnemius/plantaris, and soleus were 8%, 8%, 15%, 14%, and 18% lower, respectively, than ground controls.
  • ACVR2B/Fc improved muscle growth in flight: In flight mice, lean body mass increased by 27% over 22 days after ACVR2B/Fc treatment, compared with 18% in ground mice over the same interval; individual muscle weights at return were significantly higher than in uninjected flight mice.
  • Bone loss from spaceflight and protection by ACVR2B/Fc: In uninjected flight mice, whole-body, left femur, and right femur BMD fell by 8%, 11%, and 8% over 22 days in microgravity. ACVR2B/Fc increased BMD in ground mice by 4%, 10%, and 9% and brought BMD in flight mice to levels comparable to uninjected ground mice.
  • MicroCT showed strong skeletal protection: In femurs of uninjected flight mice, BV/TV, trabecular thickness, trabecular number, and cortical thickness were reduced by 37%, 8%, 9%, and 9%; ACVR2B/Fc increased these in ground mice by 96%, 10%, 31%, and 12%, and in flight mice the femoral BV/TV and trabecular number were described as nearly indistinguishable from ACVR2B/Fc-treated ground mice.
  • Recovery after return to Earth: After 2 weeks on Earth, untreated mice recovered muscle mass to baseline, but ACVR2B/Fc further increased muscle weights to 39%, 36%, 34%, 26%, and 20% above baseline for pectoralis, triceps, quadriceps, gastrocnemius/plantaris, and soleus, respectively; bone mass also showed conservation or gain with treatment.

## Methods

  • Design and sample: The study sent 40 female mice to the ISS in five groups of eight: untreated wild type, ACVR2B/Fc-treated wild type, and Mstn−/− mice, plus additional wild type groups kept on Earth for postflight recovery; there were also 24 ground control mice matched to flight conditions.
  • Intervention and timing: ACVR2B/Fc was administered intraperitoneally at 175 μg per injection on scheduled days before/during/after flight; mice were analyzed either at live animal return or after 14 days of recovery on Earth.
  • Main analyses: The paper used DXA, microCT, RNAseq, SomaScan proteomics, and ELISA to assess muscle, bone, and pathway changes.

## Limitations

  • The authors state that additional studies will be required to understand the basis of the unexpected higher humerus BMD seen early in flight, so that result remains unexplained in the paper.
  • They state they did not measure body water content, so the apparent rapid postflight muscle recovery could partly reflect water shifts rather than true tissue recovery.
  • Evidence evident from the text: the study used female mice only, so direct generalization to males is not supported by the paper.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1073/pnas.2014716117

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1. Mitigation of skeletal muscle loss in microgravity by targeting myostatin/activin A signaling. (A) Schematic showing the timeline of interventions and procedures. The timings of DXA scans, ACVR2B/Fc injections, and euthanasia are shown by orange, black, and green arrows, respectively. The timeline for mice in groups 1 to 3 is labeled as “flight,” and the timeline for mice in groups 4 to 5 is labeled as “recovery” (see Methods for group designations). (B) Effect of microgravity on lean body mass (Upper) and muscle weights (Lower) expressed as percent differences relative to uninjected ground mice at LAR. Bars in Lower represent pectoralis (red), triceps (gray), quadriceps (blue), gastrocnemius/plantaris (green), and soleus (orange) muscles. G, ground control mice; F, flight mice. (C) Percent differences in muscle weights in flight relative to corresponding ground mice at LAR. Bars represent muscles as described in B. None of the differences seen in Mstn −/− mice were statistically significant. (D) Changes in lean body mass (Upper) and total body fat (Lower) between the two in-flight DXA scans on days L+6 and L+28. In the Upper, percent differences in lean mass were calculated relative to ground mice at day L+6 (i.e., all numbers were normalized to ground mice at day +6, which was set to zero).a P < 0.05, b P < 0.01, c P < 0.001 versus uninjected ground mice; d P < 0.01, e P < 0.001 versus ACVR2B/Fc-injected ground mice.
Fig. 1. Mitigation of skeletal muscle loss in microgravity by targeting myostatin/activin A signaling. (A) Schematic showing the timeline of interventions and procedures. The timings of DXA scans, ACVR2B/Fc injections, and euthanasia are shown by orange, black, and green arrows, respectively. The timeline for mice in groups 1 to 3 is labeled as “flight,” and the timeline for mice in groups 4 to 5 is labeled as “recovery” (see Methods for group designations). (B) Effect of microgravity on lean body mass (Upper) and muscle weights (Lower) expressed as percent differences relative to uninjected ground mice at LAR. Bars in Lower represent pectoralis (red), triceps (gray), quadriceps (blue), gastrocnemius/plantaris (green), and soleus (orange) muscles. G, ground control mice; F, flight mice. (C) Percent differences in muscle weights in flight relative to corresponding ground mice at LAR. Bars represent muscles as described in B. None of the differences seen in Mstn −/− mice were statistically significant. (D) Changes in lean body mass (Upper) and total body fat (Lower) between the two in-flight DXA scans on days L+6 and L+28. In the Upper, percent differences in lean mass were calculated relative to ground mice at day L+6 (i.e., all numbers were normalized to ground mice at day +6, which was set to zero).a P < 0.05, b P < 0.01, c P < 0.001 versus uninjected ground mice; d P < 0.01, e P < 0.001 versus ACVR2B/Fc-injected ground mice.CC BY-NC-ND · PubMed Central
Fig. 2. Mitigation of bone loss in microgravity by targeting myostatin/activin A signaling. (A) Changes in bone mineral density between the two in-flight DXA scans on days L+6 and L+28. Percent differences were calculated relative to ground mice at day L+6 (i.e., all numbers were normalized to ground mice at day +6, which was set to zero). (B) Changes in BMC. Percent differences were calculated relative to ground mice at day L-6 (i.e., all numbers were normalized to ground mice at day l-6, which was set to zero). (C) Representative microCT images of femurs and L4 vertebrae. a P < 0.05, b P < 0.01, c P < 0.001 versus uninjected ground mice; d P < 0.05, e P < 0.001, f P < 0.001 versus ACVR2B/Fc-injected ground mice.
Fig. 2. Mitigation of bone loss in microgravity by targeting myostatin/activin A signaling. (A) Changes in bone mineral density between the two in-flight DXA scans on days L+6 and L+28. Percent differences were calculated relative to ground mice at day L+6 (i.e., all numbers were normalized to ground mice at day +6, which was set to zero). (B) Changes in BMC. Percent differences were calculated relative to ground mice at day L-6 (i.e., all numbers were normalized to ground mice at day l-6, which was set to zero). (C) Representative microCT images of femurs and L4 vertebrae. a P < 0.05, b P < 0.01, c P < 0.001 versus uninjected ground mice; d P < 0.05, e P < 0.001, f P < 0.001 versus ACVR2B/Fc-injected ground mice.CC BY-NC-ND · PubMed Central
Fig. 3. Recovery of muscle and bone mass during the 2-wk recovery period following return to Earth. Effect of 14 d of treatment with ACVR2B/Fc on (A) lean body mass and femur BMD (by DXA), (B) muscle weights, and (C) femurs and L4 vertebrae (by microCT). Bars in B represent pectoralis (red), triceps (gray), quadriceps (blue), gastrocnemius/plantaris (green), and soleus (orange) muscles. Numbers represent percent differences relative to uninjected ground mice at LAR (i.e., all numbers were normalized to uninjected ground mice at day L+35, which was set to zero). a P < 0.05, b P < 0.01, c P < 0.001 versus uninjected ground mice at LAR; d P < 0.01, e P < 0.001 versus uninjected flight mice at LAR; f P < 0.01, g P < 0.001 versus uninjected flight mice on day 49.
Fig. 3. Recovery of muscle and bone mass during the 2-wk recovery period following return to Earth. Effect of 14 d of treatment with ACVR2B/Fc on (A) lean body mass and femur BMD (by DXA), (B) muscle weights, and (C) femurs and L4 vertebrae (by microCT). Bars in B represent pectoralis (red), triceps (gray), quadriceps (blue), gastrocnemius/plantaris (green), and soleus (orange) muscles. Numbers represent percent differences relative to uninjected ground mice at LAR (i.e., all numbers were normalized to uninjected ground mice at day L+35, which was set to zero). a P < 0.05, b P < 0.01, c P < 0.001 versus uninjected ground mice at LAR; d P < 0.01, e P < 0.001 versus uninjected flight mice at LAR; f P < 0.01, g P < 0.001 versus uninjected flight mice on day 49.CC BY-NC-ND · PubMed Central
Fig. 4. Changes in plasma protein profiles as a result of ACVR2B/Fc treatment and microgravity. (A) Heat maps showing the 50 most up-regulated and 50 most down-regulated proteins identified by SomaScan analysis and sorted by ACVR2B/Fc-treated versus uninjected ground mice at 5 wk (Upper group of 5 heat maps) or by ACVR2B/Fc-treated versus uninjected flight mice during the 2-wk recovery period after return to Earth (Lower group of two heat maps). (B) Differences in plasma levels of TGF-β family members. Numbers indicate log2 of the ratios of protein levels determined by SomaScan analysis in ACVR2B/Fc-treated versus uninjected mice or flight versus ground uninjected mice. (C) Relative RNA levels of Mstn and Gdf11 in muscle and/or bone determined by RNAseq analysis. (D) Plasma concentrations of MSTN determined by ELISA. G, ground; F, flight; R, recovery. a P < 0.05, b P < 0.01, c P < 0.001 versus uninjected ground mice; d P < 0.001 versus uninjected flight mice.
Fig. 4. Changes in plasma protein profiles as a result of ACVR2B/Fc treatment and microgravity. (A) Heat maps showing the 50 most up-regulated and 50 most down-regulated proteins identified by SomaScan analysis and sorted by ACVR2B/Fc-treated versus uninjected ground mice at 5 wk (Upper group of 5 heat maps) or by ACVR2B/Fc-treated versus uninjected flight mice during the 2-wk recovery period after return to Earth (Lower group of two heat maps). (B) Differences in plasma levels of TGF-β family members. Numbers indicate log2 of the ratios of protein levels determined by SomaScan analysis in ACVR2B/Fc-treated versus uninjected mice or flight versus ground uninjected mice. (C) Relative RNA levels of Mstn and Gdf11 in muscle and/or bone determined by RNAseq analysis. (D) Plasma concentrations of MSTN determined by ELISA. G, ground; F, flight; R, recovery. a P < 0.05, b P < 0.01, c P < 0.001 versus uninjected ground mice; d P < 0.001 versus uninjected flight mice.CC BY-NC-ND · PubMed Central
Fig. 5. Changes in protein and RNA levels for components of RANK, hedgehog, Wnt, and RAGE signaling pathways. (A) Log2 of the ratios of protein levels determined by SomaScan analysis in ACVR2B/Fc-treated versus uninjected mice or flight versus ground uninjected mice. (B) Relative RNA levels of TRAIL and RANKL in muscle and/or bone determined by RNAseq analysis. (C) Plasma concentrations of OPG determined by ELISA. G, ground; F, flight; R, recovery. a P < 0.05, b P < 0.01, c P < 0.001 versus uninjected mice; d P < 0.05, e P < 0.01, f P < 0.001 versus uninjected ground mice; g P < 0.05, h P < 0.001 versus uninjected flight mice.
Fig. 5. Changes in protein and RNA levels for components of RANK, hedgehog, Wnt, and RAGE signaling pathways. (A) Log2 of the ratios of protein levels determined by SomaScan analysis in ACVR2B/Fc-treated versus uninjected mice or flight versus ground uninjected mice. (B) Relative RNA levels of TRAIL and RANKL in muscle and/or bone determined by RNAseq analysis. (C) Plasma concentrations of OPG determined by ELISA. G, ground; F, flight; R, recovery. a P < 0.05, b P < 0.01, c P < 0.001 versus uninjected mice; d P < 0.05, e P < 0.01, f P < 0.001 versus uninjected ground mice; g P < 0.05, h P < 0.001 versus uninjected flight mice.CC BY-NC-ND · PubMed Central
Fig. 6. RNAseq analysis. Bar graph showing the top 37 pathways in bone exhibiting differentially expressed transcripts between ACRVR2B/Fc-treated and uninjected ground mice. Pathways are rank-ordered based on P values. Sizes of bars indicate the number of genes within a pathway showing statistically significant differences.
Fig. 6. RNAseq analysis. Bar graph showing the top 37 pathways in bone exhibiting differentially expressed transcripts between ACRVR2B/Fc-treated and uninjected ground mice. Pathways are rank-ordered based on P values. Sizes of bars indicate the number of genes within a pathway showing statistically significant differences.CC BY-NC-ND · PubMed Central
Fig. 7. Relative RNA levels of various components of the (A) hedgehog, (B) TGF-β family, and (C) Wnt signaling pathways. Numbers indicate log2 of the ratios of RNA levels determined by RNAseq analysis of ACVR2B/Fc-treated versus uninjected mice (in A) or flight versus ground uninjected mice (in B and C). a P < 0.05, b P < 0.01, c P < 0.001 versus uninjected (in A) or ground (in B and C) mice.
Fig. 7. Relative RNA levels of various components of the (A) hedgehog, (B) TGF-β family, and (C) Wnt signaling pathways. Numbers indicate log2 of the ratios of RNA levels determined by RNAseq analysis of ACVR2B/Fc-treated versus uninjected mice (in A) or flight versus ground uninjected mice (in B and C). a P < 0.05, b P < 0.01, c P < 0.001 versus uninjected (in A) or ground (in B and C) mice.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

27 Valid · 1 Not valid · 4 Not checked · 73 Own results and interpretations

44 more claims · 2 with their cited sources checked

Create a free account to see all 105 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 36
  • Probably not a substantial claim. 30

Create a free account to see these claims.

Citations

Cites

Show all 54 references

Cited by

See all 115

Metadata

Authors
Lee, S.-J., Lehar, A., Meir, J. U., Koch, C., Morgan, A., Warren, L. E., Rydzik, R., Youngstrom, D. W., Chandok, H., George, J., Gogain, J., Michaud, M., Stoklasek, T. A., Liu, Y., & Germain-Lee, E. L.
Affiliations
  • University of Connecticut (US)
  • The Jackson Laboratory for Genomic Medicine (US)
  • National Aeronautics and Space Administration (US)
  • Center for the Advancement of Science in Space (US)
  • SomaLogic (United States) (US)
  • Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT 06030;
Corresponding author
Lee, Se-Jin
Venue
Proceedings of the National Academy of Sciences
Published
2020-09-08
Volume
117
Issue
38
Pages
23942-23951
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W3084261347
Cited by
115
References
54
Citations by year
2026: 13 · 2025: 15 · 2024: 17 · 2023: 21 · 2022: 19 · 2021: 27 · 2020: 3
FWCI
10.51
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
Funders
  • HHS | National Institutes of Health (R01AG052962, R01AR060636)
  • Center for the Advancement of Science in Space (UA-2019-031)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Spaceflight effects on biology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Social Sciences › Political Science and International Relations › Space exploration and regulation
Keywords
myostatin, activin A, ACVR2B, microgravity, spaceflight, disuse atrophy, muscle atrophy, bone loss, skeletal muscle, bone mass, signaling pathways
MeSH terms
Animals, Bone Resorption, Female, Male, Mice, Inbred C57BL, Muscular Atrophy, Space Flight, Signal Transduction, Mice, Knockout, Muscle, Skeletal, Activins, Activin Receptors, Type II, Mice, Myostatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight. https://app.cochat.ai/papers/10.1073/pnas.2014716117
The paper
Lee, S.-J., Lehar, A., Meir, J. U., Koch, C., Morgan, A., Warren, L. E., Rydzik, R., Youngstrom, D. W., Chandok, H., George, J., Gogain, J., Michaud, M., Stoklasek, T. A., Liu, Y., & Germain-Lee, E. L. (2020). Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2014716117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.